Alberto Mazza1,2, Laura Schiavon3, Gianluca Rigatelli4, Gioia Torin5, Salvatore Lenti6. 1. Internal Medicine Unit, ESH Excellence Hypertension Centre, Santa Maria della Misericordia General Hospital, AULSS 5 Polesana, Viale Tre Martiri 140, 45100, Rovigo, Italy. alberto.mazza@aulss5.veneto.it. 2. Italian Nutraceutical Society (SINut), Triveneto Area, Rovigo, Italy. alberto.mazza@aulss5.veneto.it. 3. Department of Medicine, S. Maria della Misericordia Hospital, AULSS 5 Polesana, Rovigo, Italy. 4. Interventional Cardiology Unit, Division of Cardiology, S. Maria della Misericordia Hospital, AULSS 5 Polesana, Rovigo, Italy. 5. Unit of Internal Medicine C, Department of Medicine, University of Verona, Verona, Italy. 6. Hypertension Centre and Internal Medicine and Geriatrics, San Donato Hospital, USL 8, Arezzo, Italy.
Abstract
INTRODUCION: Treatment strategies for patients with pre-hypertension and low-moderate cardiovascular (CV) risk may include nutraceutical compounds (NCs). AIM: To investigate the efficacy and safety of a new-generation of NC in lowering BP values and improving metabolic profile, in a group of hyper-cholesterolemic subjects with pre-hypertension. METHODS: 131 subjects with pre-hypertension (systolic BP 130-139 mmHg and/or diastolic BP 85-89 mmHg) without organ damage and history of CV diseases were enrolled. 66 subjects were treated with a once-daily oral formulation of a NC (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months, while 65 patients followed a diet only. Differences in serum total cholesterol (TC), low- and high-density lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG), glycemia, creatine phosphokinase (CPK), aspartate aminotransferase (AST) alanine aminotransferase (ALT) and body mass index (BMI) were evaluated. RESULTS: At the end of treatment, significant reductions of TC, LDLC, TG glucose levels were observed in both treatment groups, while HDLC values increased in the active treatment group only. A greater reduction of TC, LDLC and glycemia was observed in the treatment group. TG levels were not different within the two groups. BP and BMI levels remained unchanged, as well AST, ALT; CPK slightly increased in both groups, but it remained in the normal range. CONCLUSIONS: In patients with pre-hypertension, NC supplementation was safe, well tolerated and effective in improving lipid pattern and glucose levels and in preventing the progression to overt hypertension.
INTRODUCION: Treatment strategies for patients with pre-hypertension and low-moderate cardiovascular (CV) risk may include nutraceutical compounds (NCs). AIM: To investigate the efficacy and safety of a new-generation of NC in lowering BP values and improving metabolic profile, in a group of hyper-cholesterolemic subjects with pre-hypertension. METHODS: 131 subjects with pre-hypertension (systolic BP 130-139 mmHg and/or diastolic BP 85-89 mmHg) without organ damage and history of CV diseases were enrolled. 66 subjects were treated with a once-daily oral formulation of a NC (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months, while 65 patients followed a diet only. Differences in serum total cholesterol (TC), low- and high-density lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG), glycemia, creatine phosphokinase (CPK), aspartate aminotransferase (AST) alanine aminotransferase (ALT) and body mass index (BMI) were evaluated. RESULTS: At the end of treatment, significant reductions of TC, LDLC, TG glucose levels were observed in both treatment groups, while HDLC values increased in the active treatment group only. A greater reduction of TC, LDLC and glycemia was observed in the treatment group. TG levels were not different within the two groups. BP and BMI levels remained unchanged, as well AST, ALT; CPK slightly increased in both groups, but it remained in the normal range. CONCLUSIONS: In patients with pre-hypertension, NC supplementation was safe, well tolerated and effective in improving lipid pattern and glucose levels and in preventing the progression to overt hypertension.
Authors: Ethan M Balk; Athina Tatsioni; Alice H Lichtenstein; Joseph Lau; Anastassios G Pittas Journal: Diabetes Care Date: 2007-05-22 Impact factor: 19.112
Authors: Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak Journal: J Hypertens Date: 2008-07 Impact factor: 4.844